Agenus Inc. Options
AGEN options chain
Explore expirations, strikes, liquidity, live quotes and Greeks in the context of the same company overview.
Options Chain SnapshotA bounded snapshot of up to 200 active contracts in the displayed expiration and strike window. Close and open interest are reference fields, not live quotes.
Up to 200 active AGEN contracts expiring in the next 7–45 days, with strikes within ±25% of the current price.
| Expiration | Days to expiry | Shown contracts |
|---|---|---|
| 2026-11-20 | 14 | 6 |
| 2026-12-18 | 42 | 6 |
| Type | Strike | Expiry | Open interest | Close |
|---|---|---|---|---|
| Call | $6.00 | 2026-11-20 | 417 | $1.00 |
| Call | $7.00 | 2026-11-20 | 1,191 | $0.70 |
| Call | $8.00 | 2026-11-20 | 1,236 | $0.15 |
| Put | $6.00 | 2026-11-20 | 95 | $0.40 |
| Put | $7.00 | 2026-11-20 | 527 | $0.73 |
| Put | $8.00 | 2026-11-20 | 73 | $1.28 |
| Call | $6.00 | 2026-12-18 | — | — |
| Call | $7.00 | 2026-12-18 | 1 | $0.60 |
| Call | $8.00 | 2026-12-18 | 1 | $0.55 |
| Put | $6.00 | 2026-12-18 | — | — |
| Put | $7.00 | 2026-12-18 | — | — |
| Put | $8.00 | 2026-12-18 | — | — |
- Source
- US listed-options contracts feed
- Observed
- Cadence
- Five-minute cached contract snapshot
- Status
- fresh
Live Quotes & GreeksThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Options Ideas & Decision IntelligenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Asset BackgroundSource-supported background about this asset. The sources and review status are listed with the reference.
AGEN options refer to AGENUS INC as their underlying. Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does AGENUS INC operate?
- Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- How do AGEN options relate to the underlying company?
- The published options record identifies AGEN as an underlying symbol. Options contracts reference that underlying; expiration, strike and option type define each separate contract.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification